新型冠状病毒肺炎危重症患者有创机械通气的时机
该研究回顾性纳入2020年1月1日至3月10日武汉两家医院收治的657例患者中的40例接受有创机械通气的COVID-19危重症患者,其中31例死亡、9例存活出院。存活者从无创机械通气或高流量鼻导管氧疗至插管的间隔中位数为7小时(IQR 2-42小时),死亡者为54小时(IQR 28-143小时)。当该间隔小于50小时且插管前APACHE II评分小于10或PSI评分小于100时,死亡率可降至60%或以下。作者认为,在符合有创机械通气指征的危重症患者中,无创通气或高流量氧疗后早期初始插管可能有助于降低死亡率。
要点
- 40例接受有创机械通气的COVID-19危重症患者中31例死亡、9例存活出院,死亡者年龄大于存活者。
- 存活者无创通气或高流量氧疗至插管的间隔中位数为7小时(IQR 2-42小时),死亡者为54小时(IQR 28-143小时)。
- 无创通气或高流量氧疗至插管间隔小于50小时且插管前APACHE II评分小于10或PSI评分小于100时,死亡率可降至60%或以下。
- 无创通气或高流量氧疗至插管间隔延长及插管前APACHE II、PSI评分高与危重症患者死亡率升高相关。
- 作者认为,考虑APACHE II和PSI评分可能有助于医生决定插管时机以降低后续死亡率。
适用人群与场景
- 2020年1月1日至3月10日入住武汉中南医院急诊重症监护病房及武汉协和医院隔离病房的COVID-19危重症患者。
- 共657例住院患者中,40例需要有创机械通气并纳入分析。
研究设计与关键结果
- 回顾性病例系列,纳入40例接受有创机械通气的COVID-19危重症患者,31例死亡,9例存活出院。
- 中位年龄70岁(IQR 62-76岁),死亡者年龄大于存活者。
- 存活者无创通气或高流量氧疗至插管的间隔中位数为7小时(IQR 2-42小时),死亡者为54小时(IQR 28-143小时)。
- 无创通气或高流量氧疗至插管间隔小于50小时(约2个日历日)且插管前APACHE II评分小于10或PSI评分小于100时,死亡率可降至60%或以下。
- 无创通气或高流量氧疗至插管间隔延长及插管前APACHE II和PSI评分高与危重症患者死亡率升高相关。
- 死亡者治疗过程中多器官损伤常见。
证据类型、等级与局限
- 证据类型:回顾性病例系列(治疗性研究),证据等级为level V。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在符合有创机械通气指征的COVID-19危重症患者中,无创通气或高流量氧疗后早期初始插管可能有助于降低死亡率。
- 作者认为,考虑APACHE II和PSI评分可能有助于医生决定插管时机以降低后续死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Invasive mechanical ventilation (IMV) is a lifesaving strategy for critically ill patients with coronavirus disease 2019 (COVID-19). We aim to report the case series of critical patients receiving IMV in Wuhan and to discuss the timing of IMV in these patients.
METHODS: Data of 657 patients admitted to emergency intensive care unit of Zhongnan Hospital and isolated isolation wards of Wuhan Union Hospital from January 1 to March 10, 2020, were retrospectively reviewed. All medical records of 40 COVID-19 patients who required IMV were collected at different time points, including baseline (at admission), before receiving IMV, and before death or hospital discharge.
RESULTS: Among 40 COVID-19 patients with IMV, 31 died, and 9 survived and was discharged. The median age was 70 years (interquartile range [IQR], 62-76 years), and nonsurvivors were older than survivors. The median period from the noninvasive mechanic ventilation (NIV) or high-flow nasal cannula oxygen therapy (HFNC) to intubation was 7 hours (IQR, 2-42 hours) in IMV survivors and 54 hours (IQR, 28-143 hours) in IMV nonsurvivors. We observed that, when the time interval from NIV/HFNC to intubation was less than 50 hours (about 2 calendar days), together with Acute Physiology and Chronic Health Evaluation II (APACHE II) score of less than 10 or pneumonia severity index (PSI) score of less than 100, mortality can be reduced to 60% or less. Prolonged interval from NIV/HFNC to intubation and high levels of APACHE II and PSI before intubation were associated with higher mortality in critically ill patients. Multiple organ damage was common among these nonsurvivors in the course of treatment.
CONCLUSION: Early initial intubation after NIV/HFNC might have a beneficial effect in reducing mortality for critically ill patients meeting IMV indication. Considering APACHE II and PSI scores might help physicians in decision making about timing of intubation for curbing subsequent mortality.
LEVEL OF EVIDENCE: Therapeutic, level V.
参考来源
- Zhang Q, Shen J, Chen L, et al. Timing of invasive mechanic ventilation in critically ill patients with coronavirus disease 2019. J Trauma Acute Care Surg. 2020. PMID: 32925581. doi:10.1097/TA.0000000000002939
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。